• Return to Headlines

Shares of Neurocrine Biosc Has Risen Above Previous 52-Week High

By David Diaz

Neurocrine Biosc (NASDAQ:NBIX) traded today at a new 52-week high of $126.98. Approximately 108,000 shares have changed hands today, as compared to an average 30-day volume of 692,000 shares.

Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The Company is developing therapeutic interventions for anxiety, depression, alzheimer's disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes.

Based on a current price of $123.08, Neurocrine Biosc is currently 11.7% above its average consensus analyst price target of $108.62. Neurocrine Biosc shares have support at the 50-day moving average (MA) of $112.08 and additional support at the 200-day MA of $91.51.

In the past 52 weeks, Neurocrine Biosc share prices have been bracketed by a low of $55.95 and a high of $126.98 and are now at $123.08, 120% above that low price. The 200-day and 50-day moving averages have moved 0.80% higher and 1.22% higher over the past week, respectively.

SmarTrend recommended that subscribers consider buying shares of Neurocrine Biosc on April 30th, 2018 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $81.68. Since that recommendation, shares of Neurocrine Biosc have risen 49.0%. We continue to monitor NBIX for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: 52 week high/lows neurocrine biosc

Ticker(s): NBIX